BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 21546498)

  • 1. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
    Gunnarsson R; Mansouri L; Isaksson A; Göransson H; Cahill N; Jansson M; Rasmussen M; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Geisler C; Juliusson G; Rosenquist R
    Haematologica; 2011 Aug; 96(8):1161-9. PubMed ID: 21546498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.
    Marincevic M; Cahill N; Gunnarsson R; Isaksson A; Mansouri M; Göransson H; Rasmussen M; Jansson M; Ryan F; Karlsson K; Adami HO; Davi F; Jurlander J; Juliusson G; Stamatopoulos K; Rosenquist R
    Haematologica; 2010 Sep; 95(9):1519-25. PubMed ID: 20421269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
    Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
    Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
    Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
    Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
    Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.
    Schweighofer CD; Coombes KR; Majewski T; Barron LL; Lerner S; Sargent RL; O'Brien S; Ferrajoli A; Wierda WG; Czerniak BA; Medeiros LJ; Keating MJ; Abruzzo LV
    J Mol Diagn; 2013 Mar; 15(2):196-209. PubMed ID: 23273604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
    Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Anomaly with Potential as a New Prognostic Marker in CLL with del(13q): Gain of 16p13.3.
    Isik S; Gunden G; Gunduz E; Akay OM; Aslan A; Ozen H; Cilingir O; Erzurumluoglu Gokalp E; Kocagil S; Artan S; Gulbas Z; Durak Aras B
    Cytogenet Genome Res; 2021; 161(10-11):479-487. PubMed ID: 34915466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
    N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
    Kröber A; Seiler T; Benner A; Bullinger L; Brückle E; Lichter P; Döhner H; Stilgenbauer S
    Blood; 2002 Aug; 100(4):1410-6. PubMed ID: 12149225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
    Puiggros A; Venturas M; Salido M; Blanco G; Fernandez-Rodriguez C; Collado R; Valiente A; Ruiz-Xivillé N; Carrió A; Ortuño FJ; Luño E; Calasanz MJ; Ardanaz MT; Piñán MÁ; Talavera E; González MT; Ortega M; Marugán I; Ferrer A; Gimeno E; Bellosillo B; Delgado J; Hernández JÁ; Hernández-Rivas JM; Espinet B; ;
    Genes Chromosomes Cancer; 2014 Sep; 53(9):788-97. PubMed ID: 24915757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.
    Edelmann J; Holzmann K; Miller F; Winkler D; Bühler A; Zenz T; Bullinger L; Kühn MW; Gerhardinger A; Bloehdorn J; Radtke I; Su X; Ma J; Pounds S; Hallek M; Lichter P; Korbel J; Busch R; Mertens D; Downing JR; Stilgenbauer S; Döhner H
    Blood; 2012 Dec; 120(24):4783-94. PubMed ID: 23047824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia in a young population.
    Alshemmari SH; Hamdah A; Pandita R; Kunhikrishnan A
    Leuk Res; 2021 Nov; 110():106668. PubMed ID: 34492597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
    Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
    Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays.
    Hagenkord JM; Monzon FA; Kash SF; Lilleberg S; Xie Q; Kant JA
    J Mol Diagn; 2010 Mar; 12(2):184-96. PubMed ID: 20075210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients.
    Gunnarsson R; Isaksson A; Mansouri M; Göransson H; Jansson M; Cahill N; Rasmussen M; Staaf J; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Juliusson G; Rosenquist R
    Leukemia; 2010 Jan; 24(1):211-5. PubMed ID: 19741724
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: experience from India.
    Amare PS; Gadage V; Jain H; Nikalje S; Manju S; Mittal N; Gujral S; Nair R
    Indian J Cancer; 2013; 50(3):261-7. PubMed ID: 24061469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.